Track market-moving stories before they get noisy

Posted by Defense World Staff on Aug 13th, 2026

Dimensional Fund Advisors LP boosted its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) by 64.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,418,597 shares of the company’s stock after buying an additional 558,050 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.55% of Maravai LifeSciences worth $4,015,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in Maravai LifeSciences in the fourth quarter worth about $34,000. Insigneo Advisory Services LLC purchased a new position in shares of Maravai LifeSciences during the 4th quarter valued at about $34,000. Quantessence Capital LLC purchased a new position in shares of Maravai LifeSciences during the 3rd quarter valued at about $31,000. Stifel Financial Corp bought a new position in shares of Maravai LifeSciences during the 4th quarter valued at approximately $36,000. Finally, Jain Global LLC bought a new position in shares of Maravai LifeSciences during the 4th quarter valued at approximately $36,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the sale, the general counsel owned 360,767 shares in the company, valued at $1,825,481.02. The trade was a 6.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by insiders.

Maravai LifeSciences Trading Down 0.5% Shares of MRVI opened at $5.78 on Thursday. The firm has a market cap of $1.49 billion, a P/E ratio of -11.12 and a beta of 0.63. The company has a debt-to-equity ratio of 0.72, a current ratio of 5.91 and a quick ratio of 4.96. Maravai LifeSciences Holdings, Inc. has a 1 year low of $2.28 and a 1 year high of $7.44. The company has a 50 day simple moving average of $6.05 and a two-hundred day simple moving average of $4.43.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $51.44 million for the quarter, compared to the consensus estimate of $48.67 million. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.34%. On average, equities analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth A number of equities research analysts have commented on the stock. Wells Fargo & Company raised their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Wall Street Zen lowered shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a research note on Friday, May 8th. UBS Group restated a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Finally, Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Maravai LifeSciences has a consensus rating of “Hold” and a consensus target price of $6.25.

View Our Latest Stock Report on Maravai LifeSciences

Maravai LifeSciences Profile (Free Report)

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

Featured Stories Five stocks we like better than Maravai LifeSciences GE Vernova’s AI Power Boom Faces a Profit Test Cardinal Health Earnings: Can Perfection Get Priced In Twice? Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand Legacy Jet Builders Stall While Embraer Accelerates to New Highs Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report).

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINERayonier Inc. $RYN Stock Position Increased by Dimensional Fund Advisors LP

NEXT HEADLINE »AstroNova, Inc. $ALOT Shares Sold by Dimensional Fund Advisors LP

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript

Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.

Revenue for the quarter was $51.4 million, up 9% from the prior-year period. CEO Bernd Brust said the performance extended momentum established in the first quarter, led by demand in TriLink Biotechnologies’ mRNA-related products and continued growth at Cygnus Technologies.

TriLink revenue increased 12% year over year, while Cygnus revenue rose 3%, its fifth consecutive quarter of growth, according to the company. TriLink accounted for 67% of total revenue during the quarter, and Cygnus represented the remaining 33%.

mRNA and GMP Consumables Drive TriLink Growth Within TriLink, discovery mRNA revenue increased 17% year over year, supported by demand from larger preclinical programs. GMP consumables revenue rose 55%, driven by large CleanCap clinical orders and the company’s first GMP enzyme order. Maravai said it recorded no COVID-related GMP revenue in the second quarter.

Brust said the company views its discovery mRNA business as an early indicator of future clinical-grade demand, because customers may progress from research and preclinical work into clinical development and subsequently require GMP materials.

TriLink added 67 new discovery mRNA customers during the quarter, a record for the company, while its e-commerce platform generated record quarterly revenue. Management said the online channel has supported customer acquisition and ordering automation, particularly among earlier-stage research customers.

The company also said four new customers transitioned to GMP products in the second quarter, bringing the total to six for the year. Management continues to expect nine customer transitions to GMP during 2026, while noting there could be upside depending on customer timing.

Maravai introduced a GMP-grade enzyme portfolio during the quarter and shipped its first enzyme order. It also plans to launch GMP-grade ModTail later in 2026, though Brust said the company does not expect orders for that product until 2027. More than 125 customers were actively using ModTail one year after its commercial launch, the company said.

Cygnus Delivers Recurring Revenue Growth Cygnus generated $11.4 million in adjusted EBITDA during the quarter, representing a 68% margin. The business benefited from demand for host cell protein, or HCP, and ELISA kits, as well as distributor-order timing in China, CFO Raj Asarpota said.

Cygnus also launched a residual protein A Mix-N-Go kit and continued investing in mass spectrometry analytical services. Management said the services business has a longer sales cycle but is seeing growing customer engagement and repeat business. The company did not disclose specific revenue contribution from its MockV product line, describing it as a small but growing contributor to Cygnus.

Margins Improve as Cost Actions Take Effect Maravai’s adjusted gross margin expanded by more than 1,600 basis points from a year earlier to 58.9%. Adjusted EBITDA was $8.7 million, an improvement of more than $19 million year over year, which management attributed to stronger revenue, favorable mix toward higher-margin GMP and discovery mRNA products, and operating-expense discipline.

The company reported a GAAP net loss before non-controlling interest of $21.6 million, compared with a $69.8 million loss in the second quarter of 2025. Basic and diluted loss per share was $0.08, improving from a $0.27 loss per share a year earlier. Adjusted loss per share was $0.02, compared with $0.08 in the prior-year period.

Maravai ended the quarter with $70.1 million in cash and $147.1 million in debt. In June, the company refinanced its term loan, reduced borrowings to about $150 million, and extended the debt maturity to 2032.

Revenue Outlook Maintained; EBITDA Forecast Raised Maravai maintained its 2026 revenue guidance of $205 million to $215 million, representing expected growth of 10% to 16% over 2025. The company continues to expect TriLink revenue to grow in the high teens and Cygnus revenue to rise at a low- to mid-single-digit rate.

However, the company raised its full-year adjusted EBITDA guidance to $33 million to $35 million, representing an expected year-over-year improvement of $64 million to $66 million. It also now expects adjusted gross-margin expansion of more than 1,400 basis points for the year.

Management said it kept revenue guidance unchanged because CDMO projects and large GMP consumables orders can be substantial and their timing depends on customer program schedules. Brust said the company sees growth in smaller and midsized orders and described the revenue outlook as a prudent reflection of potential variability in larger orders.

Maravai provided investors with a new framework for assessing TriLink’s operations, separating the business conceptually into mRNA, CDMO and specialty chemistry categories while continuing to report externally through its TriLink and Cygnus operating segments. Excluding COVID-related CleanCap revenue, management said mRNA represents approximately 35% of expected 2026 revenue and is expected to grow at high-single-digit to low-double-digit rates over time.

About Maravai LifeSciences (NASDAQ:MRVI) Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates.

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million; Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million. “Our second quarter results reflect the continued execution of our strategy and the momentum we are building across the business,” said Bernd Brust, CEO of Maravai LifeSciences. “Total revenue grew 9% year over year, with TriLink increasing 12% driven by strong demand for both Discovery and GMP consumables. Cygnus delivered 3% growth marking its fifth consecutive quarter of year-over-year growth. We also generated positive Adjusted EBITDA of $8.7 million, demonstrating the operating leverage of our business model and the progress we are making toward sustainable, profitable growth.”

Brust continued, “During the quarter, we reached an important milestone with the opening of our GMP enzyme manufacturing facility, completing TriLink’s integrated portfolio of IVT raw materials and strengthening our position as a single-source partner supporting customers from early-stage research through commercial manufacturing. We also continued to see strong adoption of our ModTail™ product line which has now grown to more than 125 active customers in just one year since its commercial launch, including many of the world's leading biopharmaceutical companies. As more customer programs advance through clinical development, we believe this differentiated portfolio positions us to capture a larger share of the growing demand for GMP manufacturing materials while creating additional opportunities to participate in the long-term success of our customers’ programs.”

Revenue for the Second Quarter 2026

  Three Months Ended June 30,

(Dollars in 000’s)

2026

2025

Year-over-Year %
Change

TriLink

$

34,669

$

31,085

11.5

%

Cygnus

16,773

16,312

2.8

%

Total Revenue

$

51,442

$

47,397

8.5

%

Revenue for the Six Months Ended June 30, 2026

  Six Months Ended June 30,

(Dollars in 000’s)

2026

2025

Year-over-Year %
Change

TriLink

$

82,145

$

59,835

37.3

%

Cygnus

35,134

34,412

2.1

%

Total Revenue

$

117,279

$

94,247

24.4

%

Second Quarter 2026 Financial Results by Reporting Segment

Revenue for the second quarter was $51.4 million, an increase of 8.5% compared to the prior year period, driven by the following:

TriLink revenue increased 11.5% year-over-year, with increased demand for research use only (RUO) raw materials used in drug discovery (Discovery mRNA) and GMP products used in clinical trials (GMP consumables). Cygnus revenue increased 2.8% year-over-year, driven by increased demand for Host Cell Protein (HCP) and ELISA kits and strength in China due to distributor ordering timing. Net loss and Adjusted EBITDA (non-GAAP) were $(21.6) million and $8.7 million, respectively, for the second quarter of 2026, compared to net loss and Adjusted EBITDA (non-GAAP) of $(69.8) million and $(10.4) million, respectively, for the second quarter of 2025.

Six Months Ended June 30, 2026 Financial Results by Reporting Segment

Revenue for the six months ended June 30, 2026 increased 24.4% compared to the prior year period, driven by the following:

TriLink revenue increased 37.3% year-over-year, primarily driven by $14.3 million of high-volume CleanCap orders for commercial phase COVID vaccine programs in Q1 2026. Excluding COVID CleanCap revenue, TriLink base revenue grew 13.4% year-over-year with increased demand for both Discovery mRNA and GMP consumables. Cygnus revenue increased 2.1% year-over-year, driven by demand for HCP, ELISA and DNA detection kits. Net loss and Adjusted EBITDA (non-GAAP) were $(28.0) million and $29.0 million, respectively, for the six months ended June 30, 2026, compared to net loss and Adjusted EBITDA (non-GAAP) of $(122.7) million and $(21.0) million, respectively, for the same period in the prior year.

Updated Financial Guidance for Full Year 2026

Maravai’s financial guidance for the full year 2026 is based on expectations for its existing business and does not include the financial impact of potential new acquisitions, if any, or items that have not yet been identified or quantified. This guidance is also subject to a number of risks, uncertainties and other factors, including those identified in “Forward-looking Statements” below.

Revenue for the full year 2026 is expected to be in the range of $205.0 million to $215.0 million.

Adjusted EBITDA (non-GAAP) is now expected to be in the range of $33.0 million to $35.0 million, up from the prior range of $30.0 million to $32.0 million.

As it relates to forward-looking Adjusted EBITDA, Maravai cannot provide guidance for the most directly comparable GAAP measure or a reconciliation of this non-GAAP financial measure because it is unable to provide a meaningful or accurate calculation or estimation of certain significant reconciling items without unreasonable effort.

Conference Call and Webcast

Maravai’s management will host a conference call today at 2:00 p.m. PT/ 5:00 p.m. ET to discuss its financial results for the second quarter of 2026 and other business updates. To participate in the conference call by telephone, approximately 10 minutes before the call, dial 1-800-579-2543 or 1-785-424-1789 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com/.

MARAVAI LIFESCIENCES HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(Unaudited)

  Three Months Ended
June 30,

Six Months Ended
June 30,

2026

2025

2026

2025

Revenue

$

51,442

$

47,397

$

117,279

$

94,247

Cost of revenue

30,792

39,629

62,928

78,754

Gross profit

20,650

7,768

54,351

15,493

Operating expenses:

Selling, general and administrative

32,070

38,715

61,162

78,279

Research and development

3,702

4,882

7,591

9,770

Goodwill impairment

—

30,449

—

42,884

Restructuring

(33

)

—

2,845

—

Total operating expenses

35,739

74,046

71,598

130,933

Loss from operations

(15,089

)

(66,278

)

(17,247

)

(115,440

)

Other income (expense):

Interest expense

(4,809

)

(6,815

)

(10,558

)

(13,593

)

Interest income

1,159

3,030

3,032

6,255

Loss on extinguishment of debt

(3,011

)

—

(3,413

)

—

Other expense

(52

)

(4,062

)

(144

)

(4,038

)

Loss before income taxes

(21,802

)

(74,125

)

(28,330

)

(126,816

)

Income tax benefit

(171

)

(4,288

)

(322

)

(4,126

)

Net loss

(21,631

)

(69,837

)

(28,008

)

(122,690

)

Net loss attributable to non-controlling interests

(9,215

)

(30,246

)

(11,859

)

(53,154

)

Net loss attributable to Maravai LifeSciences Holdings, Inc.

$

(12,416

)

$

(39,591

)

$

(16,149

)

$

(69,536

)

Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted

$

(0.08

)

$

(0.27

)

$

(0.11

)

$

(0.48

)

Weighted average number of Class A common shares outstanding, basic and diluted

147,996

144,236

147,215

143,833

MARAVAI LIFESCIENCES HOLDINGS, INC.

RECONCILIATION OF NON-GAAP FINANCIAL INFORMATION

(in thousands, except per share amounts)

(Unaudited)

  Net Loss to Adjusted EBITDA (non-GAAP)

Three Months Ended
June 30,

Six Months Ended
June 30,

2026

2025

2026

2025

Net loss

$

(21,631

)

$

(69,837

)

$

(28,008

)

$

(122,690

)

Add:

Amortization

6,469

7,200

12,941

14,230

Depreciation

5,313

5,957

10,213

11,650

Interest expense

4,809

6,815

10,558

13,593

Interest income

(1,159

)

(3,030

)

(3,032

)

(6,255

)

Income tax benefit

(171

)

(4,288

)

(322

)

(4,126

)

EBITDA

(6,370

)

(57,183

)

2,350

(93,598

)

Acquisition integration costs (1)

218

831

449

1,598

Stock-based compensation (2)

10,205

6,789

16,948

17,192

Merger and acquisition related expenses (3)

—

92

—

1,270

Loss on extinguishment of debt

3,011

—

3,413

—

Acquisition related tax adjustment (4)

—

4,153

—

4,082

Executive leadership transition costs (5)

—

2,007

—

2,007

Goodwill impairment (6)

—

30,449

—

42,884

Property and equipment impairment (7)

—

1,052

—

1,052

Restructuring costs (8)

(33

)

—

3,077

—

Other (9)

1,643

1,400

2,764

2,554

Adjusted EBITDA (non-GAAP)

$

8,674

$

(10,410

)

$

29,001

$

(20,959

)

Net Loss attributable to Maravai LifeSciences Holdings, Inc. to Adjusted Net Loss (non-GAAP) and Adjusted Fully Diluted Loss Per Share (non-GAAP)

Three Months Ended
June 30,

Six Months Ended
June 30,

2026

2025

2026

2025

Net loss attributable to Maravai LifeSciences Holdings, Inc.

$

(12,416

)

$

(39,591

)

$

(16,149

)

$

(69,536

)

Net loss impact from pro forma conversion of Class B shares to Class A common shares

(9,215

)

(30,246

)

(11,859

)

(53,154

)

Adjustment to the provision for income tax (10)

2,255

7,204

2,902

12,660

Tax-effected net loss

(19,376

)

(62,633

)

(25,106

)

(110,030

)

Acquisition integration costs (1)

218

831

449

1,598

Stock-based compensation (2)

10,205

6,789

16,948

17,192

Merger and acquisition related expenses (3)

—

92

—

1,270

Loss on extinguishment of debt

3,011

—

3,413

—

Acquisition related tax adjustment (4)

—

4,153

—

4,082

Executive leadership transition costs (5)

—

2,007

—

2,007

Goodwill impairment (6)

—

30,449

—

42,884

Property and equipment impairment (7)

—

1,052

—

1,052

Restructuring costs (8)

(33

)

—

3,077

—

Other (9)

1,643

1,400

2,764

2,554

Tax impact of adjustments (11)

(773

)

(4,977

)

(2,813

)

(3,882

)

Adjusted net loss (non-GAAP)

$

(5,105

)

$

(20,837

)

$

(1,268

)

$

(41,273

)

Diluted weighted average shares of Class A common stock outstanding (non-GAAP)

267,400

255,340

266,359

255,401

Adjusted loss (non-GAAP)

$

(5,105

)

$

(20,837

)

$

(1,268

)

$

(41,273

)

Adjusted fully diluted loss per share (non-GAAP)

$

(0.02

)

$

(0.08

)

$

0.00

$

(0.16

)

____________________

Explanatory Notes to Reconciliations

(1) Refers to incremental costs incurred to execute and integrate completed acquisitions, including retention payments related to integration that were negotiated specifically at the time of the Company’s acquisition of Alphazyme, which was completed in January 2023. These retention payments were from the Company’s agreement executed in connection with its acquisition of Alphazyme and provided incremental financial incentives, over and above recurring compensation, to ensure the employees of Alphazyme remained present and participated in integration of the acquired business during the integration and knowledge transfer period. The Company agreed to pay certain employees of Alphazyme retention payments totaling $9.3 million as of various dates but primarily through December 31, 2025, as long as these individuals continued to be employed by the Company. The Company recognized compensation expense related to these payments in the post-acquisition period ratably over the service period, with certain costs capitalized into inventory. Retention payment expenses were $0.8 million and $1.4 million for the three and six months ended June 30, 2025, respectively. Retention expenses for Alphazyme concluded in the fourth quarter of 2025, and following the payments in the fourth quarter of 2025, there were no further retention expenses payable for Alphazyme. There are no further cash-based retention payments planned as of June 30, 2026. The remaining expenses incurred reflect the impact to cost of revenue for the retention bonuses previously capitalized into inventory as the inventory is sold.

(2) Refers to non-cash expense associated with stock-based compensation.

(3) Refers to diligence, legal, accounting, tax and consulting fees incurred in connection with acquisitions that were pursued but not consummated.

(4) Refers to non-cash expense associated with adjustments to the indemnification asset recorded in connection with the acquisition of MyChem.

(5) Refers to costs associated with the Executive Leadership Transition that occurred in June 2025, including severance and legal costs. For both the three and six months ended June 30, 2025, stock-based compensation benefit of $3.3 million primarily related to forfeited stock awards in connection with the Executive Leadership Transition is included on the stock-based compensation line item.

(6) Refers to goodwill impairment recorded for our TriLink segment.

(7) Refers to non-cash charges to write-down surplus laboratory equipment to estimated fair value, less costs to sell.

(8) Refers to restructuring costs (benefit) associated with the 2025 Corporate Realignment Plan. For the six months ended June 30, 2026, stock-based compensation expense of ($0.2 million) related to forfeited stock awards is included in the stock-based compensation line item.

(9) For the three and six months ended June 30, 2026 and for the three and six months ended June 30, 2025, refers to severance expense, inventory step-up charges in connection with the acquisition of Alphazyme, non-recurring legal costs, change in the estimated fair value of contingent consideration related to completed acquisitions, and other non-recurring costs that are deemed to be outside of the ordinary course of business.

(10) Represents additional corporate income taxes at an assumed effective tax rate of approximately 24% applied to additional net loss attributable to Maravai LifeSciences Holdings, Inc. from the assumed proforma exchange of all outstanding shares of Class B common stock for shares of Class A common stock.

(11) Represents income tax impact of non-GAAP adjustments at an assumed effective tax rate of approximately 24% and the assumed proforma exchange of all outstanding shares of Class B common stock for shares of Class A common stock.

Non-GAAP Financial Information

This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include: Adjusted EBITDA and Adjusted fully diluted Earnings Per Share (EPS).

Maravai defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization, certain non-cash items and other adjustments that we do not consider representative of our ongoing operating performance from period to period. Maravai defines Adjusted Net Income (Loss) as tax-effected earnings before the adjustments described above, and the tax effects of those adjustments. Maravai defines Adjusted fully diluted EPS as Adjusted Net Income (Loss) divided by the diluted weighted average number of shares of Class A common stock outstanding for the applicable period, which assumes the proforma exchange of all outstanding units of Maravai Topco Holdings, LLC (paired with shares of Class B common stock) for shares of Class A common stock.

These non-GAAP measures are supplemental measures of operating performance that are not prepared in accordance with GAAP and do not represent, and should not be considered as, an alternative to net loss, as determined in accordance with GAAP.

Management uses these non-GAAP measures to understand and evaluate Maravai’s core operating performance and trends, and to develop short-term and long-term operating plans. Management believes the measures facilitate comparison of Maravai’s operating performance on a consistent basis between periods and, when viewed in combination with its results prepared in accordance with GAAP, help provide a broader picture of factors and trends affecting Maravai’s results of operations.

These non-GAAP financial measures have limitations as an analytical tool, and you should not consider them in isolation, or as a substitute for analysis of Maravai’s results as reported under GAAP. Because of these limitations, they should not be considered as a replacement for net loss, as determined by GAAP, or as a measure of Maravai’s profitability. Management compensates for these limitations by relying primarily on Maravai’s GAAP results and using non-GAAP measures only for supplemental purposes. The non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit www.maravai.com.

Forward-looking Statements

This press release contains, and Maravai’s officers and representatives may from time-to-time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements regarding Maravai’s expected revenue and EBITDA performance for the full year 2026; durability of demand for TriLink’s Discovery and GMP consumables; the operating leverage of Maravai’s business model; Maravai’s ability to execute on its strategy to drive sustained, profitable growth; TriLink’s position as a single-source partner supporting customers from early-stage research through commercial manufacturing; continued customer adoption of TriLink’s ModTail™ product line; TriLink’s ability to capture a larger share of the growing demand for GMP manufacturing materials as more customer programs advance through clinical development; Maravai’s participation in the long-term success of our customers’ programs, constitute forward-looking statements and are identified by words like “believe,” “expect,” “see,” “project,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of Maravai’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of management’s control. Maravai’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause Maravai’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

The level of Maravai’s customers’ spending on and demand for TriLink and Cygnus products and services. Maravai’s operating results are prone to significant fluctuation, which may make Maravai’s future operating results difficult to predict and could cause Maravai’s actual operating results to fall below expectations or any guidance Maravai may provide. Uncertainty regarding the extent and duration of Maravai’s revenue associated with high-volume sales of CleanCap® for commercial phase vaccine programs and the dependency of such revenue, in important respects, on factors outside our control. Shifts in the trade, economic and other policies and priorities of the U.S. federal government, on Maravai and Maravai’s customers’ current and future business operations. Unintended consequences from our recent organizational changes and workforce reduction. Use of Maravai’s products by customers in the production of vaccines and therapies, some of which represent relatively new and still-developing modes of treatment, and the impact of unforeseen adverse events, negative clinical outcomes, development of alternative therapies, or increased regulatory scrutiny of these modes of treatment and their financial cost on Maravai’s customers’ use of its products and services. Competition with life science, pharmaceutical and biotechnology companies who are substantially larger than Maravai and potentially capable of developing new approaches that could make Maravai’s products, services and technology obsolete. The potential failure of Maravai’s products and services to perform as expected and the reliability of the technology on which Maravai’s products and services are based. Maravai’s use of Artificial Intelligence technologies, including Machine Learning, and business, compliance and reputational challenges that may result from such use. The risk that Maravai’s products do not comply with required quality standards. Market acceptance of Maravai’s life science reagents. Maravai’s ability to efficiently manage its strategic acquisitions and organic growth opportunities. Natural disasters, geopolitical instability (including ongoing military conflicts) and other catastrophic events. Risks related to Maravai’s acquisitions, including whether Maravai achieves the anticipated benefits of acquisitions of businesses or technologies. Product liability lawsuits. Maravai’s dependency on a limited number of customers for a high percentage of its revenue and Maravai’s ability to maintain its current relationships with such customers. Maravai’s reliance on a limited number of suppliers or, in some cases, sole suppliers, for some of Maravai’s raw materials and the risk that Maravai may not be able to find replacements or immediately transition to alternative suppliers. The risk that Maravai’s products become subject to more onerous regulation by the U.S. Food and Drug Administration or other regulatory agencies in the future. Maravai’s ability to obtain, maintain and enforce sufficient intellectual property protection for Maravai’s current or future products. The risk that a future cyber-attack or security breach cannot be prevented. Maravai’s ability to protect the confidentiality of Maravai’s proprietary information. The risk that one of Maravai’s products may be alleged (or found) to infringe on the intellectual property rights of third parties. Compliance with Maravai’s obligations under intellectual property license agreements. Maravai’s or Maravai’s licensors’ failure to maintain the patents or patent applications in-licensed from a third party. Maravai’s ability to adequately protect Maravai’s intellectual property and proprietary rights throughout the world. Maravai’s existing level of indebtedness and Maravai’s ability to raise additional capital on favorable terms. Maravai’s ability to generate sufficient cash flow to service all of Maravai’s indebtedness. Maravai’s potential failure to meet Maravai’s debt service obligations. Restrictions on Maravai’s current and future operations under the terms applicable to Maravai’s credit agreement. Maravai’s dependence, by virtue of Maravai’s principal asset being its interest in Maravai Topco Holdings, LLC (“Topco LLC”), on distributions from Topco LLC to pay Maravai’s taxes and expenses, including payments under a tax receivable agreement with the former owners of Topco LLC (the “Tax Receivable Agreement” or “TRA”) together with various limitations and restrictions that impact Topco LLC’s ability to make such distributions. The risk that conflicts of interest could arise between Maravai’s shareholders and Maravai Life Sciences Holdings, LLC (“MLSH 1”), the only other member of Topco LLC, and impede business decisions that could benefit Maravai’s shareholders. The substantial future cash payments Maravai may be required to make under the Tax Receivable Agreement to MLSH 1 and Maravai Life Sciences Holdings 2, LLC (“MLSH 2”), an entity through which certain of Maravai’s former owners hold their interests in the Company and the negative effect of such payments. The fact that Maravai’s organizational structure, including the TRA, confers certain benefits upon MLSH 1 and MLSH 2 that will not benefit Maravai’s other common shareholders to the same extent as they will benefit MLSH 1 and MLSH 2. Maravai’s ability to realize all or a portion of the tax benefits that are expected to result from the tax attributes covered by the Tax Receivable Agreement. The possibility that Maravai will receive distributions from Topco LLC significantly in excess of Maravai’s tax liabilities and obligations to make payments under the Tax Receivable Agreement. Factors that could lead to future impairment of Maravai’s goodwill and other amortizable intangible assets. Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of Maravai’s income or other tax returns. Maravai’s ability to design and maintain effective internal control over financial reporting in the future. The fact that investment entities affiliated with GTCR, LLC currently control a majority of the voting power of Maravai’s outstanding common stock, and it may have interests that conflict with Maravai’s or yours in the future. Risks related to Maravai’s “controlled company” status within the meaning of the corporate governance standards of NASDAQ. The potential anti-takeover effects of certain provisions in Maravai’s corporate organizational documents. Potential sales of a significant portion of Maravai’s outstanding shares of Class A common stock. Potential preferred stock issuances and the anti-takeover impacts of any such issuances. Such other factors as discussed throughout the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Maravai’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as well as other documents Maravai files with the Securities and Exchange Commission. Any forward-looking statements made in this release are based only on information currently available to management and speak only as of the date on which it is made. Maravai undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

More News From Maravai LifeSciences Holdings, Inc.

TriLink's Complete Portfolio of CleanCap® Analogs are Patented in Major Jurisdictions Globally; TriLink is the Sole Authorized Manufacturer of CleanCap® Capping Analogs

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules. The new patent covers TriLink's full suite of CleanCap® capping analogs, including its latest M6 analog. CleanCap technology is a critical component of the production of synthetic mRNA as drug developers and researchers strive to maximize the impact of mRNA-based therapeutics and vaccines.

The allowed claims are directed to co-transcriptional RNA synthesis methods utilizing either trimer or tetramer capping structures.

This new patent reinforces the global strength of TriLink's intellectual property portfolio in one of the world's most strategically important markets. CleanCap® technology is patented across major world markets in addition to China, including the United States, the European Union, Australia, Japan, Korea, Hong Kong, and Canada.

"We are committed to defending our intellectual property rights, and this new patent represents an important tool in support of those efforts," said Bernd Brust, Chief Executive Officer of Maravai LifeSciences. "Maintaining strong intellectual property coverage in every major jurisdiction is central to our strategy. We look forward to deepening our presence in this important market and bringing the gold standard in mRNA capping technology to the researchers and drug developers who are advancing the next generation of RNA-based medicines."

"CleanCap® offers significant advantages for mRNA programs," said Chanfeng Zhao, Chief Scientific Officer of TriLink BioTechnologies. "This patent reflects the depth of innovation our team has brought to mRNA manufacturing."

The technology covered by the patent enables the co-transcriptional production of mRNAs containing the major natural cap structures found in humans, a significant improvement over legacy capping methods such as enzymatic capping and ARCA. CleanCap® technology has been used in commercially approved COVID-19 mRNA and saRNA vaccines and underpins drug development programs across mRNA therapeutics, oncology, infectious diseases, rare diseases, and cell and gene therapies.

To learn more about TriLink's products and services, visit trilinkbiotech.com.

About TriLink BioTechnologies

TriLink BioTechnologies, part of Maravai LifeSciences, is a global leader in nucleic acid technologies and manufacturing solutions for RNA therapeutics, vaccines, gene editing, and diagnostics. The company's portfolio includes modified nucleotides, mRNA products, proprietary technologies such as CleanCap® capping analogs and ModTail™ technology, and a growing portfolio of high-performance enzymes marketed under the Alphazyme brand. Supported by robust GMP manufacturing capabilities, TriLink enables customers from early-stage research through commercial production.

For more information, visit trilinkbiotech.com.

About Maravai LifeSciences

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit www.maravai.com.

Forward-looking statements

This press release contains, and Maravai's officers and representatives may from time-to-time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements regarding the expected benefits associated with using CleanCap® technology, the expected impact of mRNA vaccines and therapeutics; Maravai's future business capabilities; growth opportunities, including inorganic growth; and future innovations, constitute forward-looking statements and are identified by words like "promise," "believe," "expect," "see," "project," "may," "will," "should," "seek," "anticipate," or "could" and similar expressions.

TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production.

The launch addresses a long-standing pain point for RNA therapeutics developers sourcing critical raw materials — enzymes, nucleotides, cap analogs, and tail technology — from multiple vendors with different quality systems, timelines, and points of contact. Managing different quality systems, timelines, and supply processes can slow development and create manufacturing risk. TriLink is now offering these materials as a coordinated, single-source package designed to simplify development and scale up.

The Jupiter facility was purpose-built for GMP enzyme manufacturing. It features controlled cleanroom environments, validated production processes, and scalable capacity designed to support both clinical-stage programs and commercial supply. Full traceability and quality systems are in place to meet regulatory requirements across major markets.

The facility is already supporting customer programs, with TriLink successfully shipping its first commercial GMP enzyme batch in June 2026. This milestone demonstrates the facility’s operational readiness and ability to provide commercial-scale supply of critical IVT raw materials to RNA therapeutics developers worldwide.

The facility’s flagship product is GMP CleanScribe™ RNA Polymerase that reduces double-stranded RNA (dsRNA) formation by up to 85% compared to standard Wild-type T7 RNA polymerases, a result demonstrated across internal and customer studies. dsRNA is a critical quality attribute in therapeutic mRNA manufacturing: its accumulation drives purification complexity, depresses final RNA purity, and increases immunogenicity risk in vivo. CleanScribe™ RNA Polymerase is engineered specifically for IVT workflows where controlling dsRNA at the synthesis step translates directly into downstream process efficiency and product quality.

An Integrated IVT Raw Materials Solution

TriLink BioTechnologies is now offering a coordinated supply of GMP-grade IVT raw materials:

GMP CleanScribe™ RNA Polymerase MixGMP NTPs (nucleoside triphosphates) GMP CleanCap® analogs — the industry-standard co-transcriptional capping reagents GMP ModTail™ technology — designed to enhance mRNA stability and in vivo protein expression The integrated offering is designed to reduce vendor complexity, simplify tech transfer, and ensure material consistency across the development lifecycle from IND-enabling studies through BLA submission and commercial launch.

As RNA-based therapeutics move into later-stage clinical development and commercial production, reliable access to manufacturing materials becomes increasingly important. Enzyme performance variability, regulatory gaps in supplier quality systems, and multi-vendor logistics create compounding delays at precisely the stages when speed matters most.

Combining GMP manufacturing, high-performance enzyme design, and coordinated supply with TriLink’s other GMP consumables, is intended to compress this complexity into a single, accountable partner relationship.

“RNA therapeutics developers need reliable supply partners that can support them from early research through commercial manufacturing. By combining enzyme manufacturing capabilities with TriLink’s existing RNA technologies, we help customers simplify sourcing, reduce supply chain complexity, and accelerate scale-up with greater confidence.”

— Chad Decker, SVP Global Sales, TriLink BioTechnologies

To learn more about TriLink’s new GMP enzyme capabilities visit: https://www.trilinkbiotech.com/gmp-enzymes

About TriLink BioTechnologies

TriLink BioTechnologies, part of Maravai LifeSciences, is a global leader in nucleic acid technologies and manufacturing solutions for RNA therapeutics, vaccines, gene editing, and diagnostics. The company's portfolio includes modified nucleotides, mRNA products, proprietary technologies such as CleanCap® capping analogs and ModTail™ technology, and a growing portfolio of high-performance enzymes marketed under the Alphazyme brand. Supported by robust GMP manufacturing capabilities, TriLink enables customers from early-stage research through commercial production.

About Maravai LifeSciences

Maravai LifeSciences is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260616862149/en/

Posted by Defense World Staff on Apr 6th, 2026

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) has been given a consensus recommendation of “Hold” by the five analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $5.3750.

A number of brokerages have recently commented on MRVI. Wall Street Zen raised Maravai LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Wells Fargo & Company boosted their price objective on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a report on Monday, December 15th.

Read Our Latest Report on MRVI

Maravai LifeSciences Stock Performance Shares of Maravai LifeSciences stock opened at $2.95 on Monday. The company has a current ratio of 6.60, a quick ratio of 5.69 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $758.36 million, a P/E ratio of -3.28 and a beta of 0.43. The business has a fifty day simple moving average of $3.22 and a two-hundred day simple moving average of $3.33. Maravai LifeSciences has a 12 month low of $1.66 and a 12 month high of $4.11.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last released its earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. The firm had revenue of $49.87 million for the quarter, compared to the consensus estimate of $49.06 million. On average, equities analysts forecast that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Maravai LifeSciences Large investors have recently bought and sold shares of the business. Sprott Inc. bought a new position in Maravai LifeSciences during the 3rd quarter valued at about $29,000. Quantessence Capital LLC bought a new position in Maravai LifeSciences during the third quarter valued at approximately $31,000. Abel Hall LLC purchased a new stake in Maravai LifeSciences in the third quarter worth approximately $33,000. CIBC Bancorp USA Inc. bought a new stake in Maravai LifeSciences in the 3rd quarter worth approximately $33,000. Finally, Virtu Financial LLC purchased a new stake in Maravai LifeSciences during the 4th quarter valued at $34,000. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences (Get Free Report)

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

Featured Articles Five stocks we like better than Maravai LifeSciences

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEWarner Bros. Discovery, Inc. (NASDAQ:WBD) Receives Average Rating of “Hold” from Brokerages

NEXT HEADLINE »Vertiv Holdings Co. (NYSE:VRT) Given Consensus Rating of “Moderate Buy” by Brokerages

Maravai LifeSciences Holdings, Inc. (MRVI - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for Maravai LifeSciences basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Maravai LifeSciences imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.

Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for Maravai LifeSciencesThis company is expected to earn -$0.18 per share for the fiscal year ending December 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for Maravai LifeSciences. Over the past three months, the Zacks Consensus Estimate for the company has increased 23.5%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Maravai LifeSciences to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Maravai LifeSciences Holdings, Inc. (MRVI - Free Report) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to a loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +121.41%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.04, delivering a surprise of +42.86%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Maravai LifeSciences, which belongs to the Zacks Medical - Products industry, posted revenues of $65.84 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 20.66%. This compares to year-ago revenues of $46.85 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Maravai LifeSciences shares have added about 21.2% since the beginning of the year versus the S&P 500's gain of 7.6%.

What's Next for Maravai LifeSciences?While Maravai LifeSciences has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Maravai LifeSciences was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.05 on $55.2 million in revenues for the coming quarter and -$0.18 on $205.41 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Cresco Labs Inc. (CRLBF - Free Report) , is yet to report results for the quarter ended March 2026.

This company is expected to post quarterly loss of $0.03 per share in its upcoming report, which represents a year-over-year change of +25%. The consensus EPS estimate for the quarter has been revised 30% higher over the last 30 days to the current level.

Cresco Labs Inc.'s revenues are expected to be $148.64 million, down 10.3% from the year-ago quarter.

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June. On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City, NY. A live webcast of the fireside chat will be on th.

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility and a $30 million revolving credit facility. Borrowings under the new term loan facility, together with approximately $98.5 million of cash on hand, were used to prepay outs.